<code id='C2D505F907'></code><style id='C2D505F907'></style>

<acronym id='C2D505F907'></acronym>

<center id='C2D505F907'><center id='C2D505F907'><tfoot id='C2D505F907'></tfoot></center><abbr id='C2D505F907'><dir id='C2D505F907'><tfoot id='C2D505F907'></tfoot><noframes id='C2D505F907'>

<optgroup id='C2D505F907'><strike id='C2D505F907'><sup id='C2D505F907'></sup></strike><code id='C2D505F907'></code></optgroup>

<b id='C2D505F907'><label id='C2D505F907'><select id='C2D505F907'><dt id='C2D505F907'><span id='C2D505F907'></span></dt></select></label></b><u id='C2D505F907'></u>

~~<i id='C2D505F907'><strike id='C2D505F907'><tt id='C2D505F907'><pre id='C2D505F907'></pre></tt></strike></i>~~

Home» comprehensive» Wikipedia

Wikipedia

Wikipedia

author：fashion 2025-09-27 20:22:14 Page View：82

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

advertisement

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： What to expect at HLTH 2023, the health care industry conference
Next article： Activists slam private health insurers over coverage restrictions

explore

In Memoriam: Notable people who died in 2023

In Memoriam: Notable people who died in 2023

1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel

Why age limits for politicians are a terrible idea

Why age limits for politicians are a terrible idea

AdobeArecentpollfromYouGov/CBSNewsshowedthat77%ofrespondentssaidthatthereshouldbeamaximumagelimitfor

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

CourtesyBristolMyersSquibbBristolMyersSquibbsaidthatitwouldpurchaseMiratiTherapeutics,makerofthecanc

read more